Intelligenome
Private Company
Funding information not available
Overview
IntelliGenome is an early-stage diagnostics company leveraging CRISPR technology to build a high-throughput, point-of-care testing platform. The company's core mission is to accelerate disease detection by moving diagnostic capabilities out of centralized labs and into decentralized settings, with an initial focus on tuberculosis (TB). While still in development, its platform promises ultra-sensitive, rapid, and quantitative results for both pathogen identification and monitoring treatment efficacy. The company appears to be in a pre-revenue, R&D-focused stage, collaborating with public health agencies and academic institutions.
Technology Platform
Proprietary CRISPR-based molecular diagnostic platform designed for ultra-sensitive, quantitative, and rapid detection of pathogens at the point-of-care. Aims to provide high-throughput capabilities in a decentralized format.
Opportunities
Risk Factors
Competitive Landscape
The CRISPR diagnostics field is competitive, with well-funded players like Sherlock Biosciences and Mammoth Biosciences developing similar platforms. IntelliGenome must differentiate through superior quantitation, sensitivity, or specific partnerships in high-priority disease areas like tuberculosis to gain traction.